The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A randomized phase II trial evaluating CYP2D6 genotype-guided tamoxifen dosing in hormone receptor-positive metastatic breast cancer: TARGET-1.
 
Toshimi Takano
Honoraria - Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Hakko Kirin; Novartis; Taiho Pharmaceutical
Research Funding - Chugai Pharma (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Puma Biotechnology (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Chiyo K. Imamura
Employment - Amgen (I); Gilead Sciences (I)
Honoraria - Chugai Pharma
Consulting or Advisory Role - Ono Pharmaceutical
 
Kenji Tamura
No Relationships to Disclose
 
Shigehira Saji
Honoraria - AstraZeneca; Chugai Pharma; Eisai; Kyowa Hakko Kirin; Novartis; Takeda
Research Funding - Chugai/Roche (Inst); Daiichi Sankyo (Inst); Eisai (Inst)
 
Takeharu Yamanaka
Honoraria - Boehringer Ingelheim; Chugai Pharma; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Gilead Sciences
Research Funding - Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Kan Yonemori
Honoraria - Eisai; Novartis; Taiho Pharmaceutical
Research Funding - Ono Pharmaceutical
 
Masato Takahashi
Speakers' Bureau - AstraZeneca; Eisai
 
Junji Tsurutani
Honoraria - AstraZeneca; Eisai; Kyowa Hakko Kirin; Novartis; Roche; Taiho Pharmaceutical
Consulting or Advisory Role - Asahi Kasei; Eisai
Research Funding - Daiichi Sankyo (Inst); Eisai (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Daiichi Sankyo; Novartis
 
Reiki Nishimura
Honoraria - Chugai Pharma
 
Kazuhiko Sato
No Relationships to Disclose
 
Akira Kitani
No Relationships to Disclose
 
Naoto T. Ueno
Honoraria - Kyowa Hakko Kirin
Research Funding - Amgen; Bayer; Bio-Path Holdings; Celgene; Daiichi Sankyo; GlaxoSmithKline; Kyowa Hakko Kirin; Medivation; Merck; Novartis; Puma Biotechnology
Travel, Accommodations, Expenses - Kyowa Hakko Kirin
 
Taisei Mushiroda
No Relationships to Disclose
 
Michiaki Kubo
No Relationships to Disclose
 
Yasuhiro Fujiwara
Honoraria - AstraZeneca Japan; Chugai Pharma; Daiichi Sankyo; Novartis; Taiho Pharmaceutical
 
Yusuke Tanigawara
Speakers' Bureau - Chugai Pharma
Research Funding - Taiho Pharmaceutical